• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

2.060 -0.340 (-14.17%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 379,602
Open 2.400
Bid (Size) 2.000 (300)
Ask (Size) 2.880 (100)
Prev. Close 2.400
Today's Range 2.010 - 2.400
52wk Range 1.300 - 4.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts ↗
October 16, 2026
Adagene (NASDAQ:ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company’s antibody pipeline, its approach to masked therapies and upcoming development milestones... 
Via MarketBeat
News headline image
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
October 14, 2026
From Adagene Inc.
Via GlobeNewswire

Performance

52-Week Range 57.5% below 52-week high
2.060
1.3052W Low 4.8552W High
1 Week 27.9% below 1-week high
2.011W Low 2.861W High

Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG) traded between $1.30 and $4.85 over the past 52 weeks and last traded at $2.06, 57.5% below its 52-week high. Over the past week it ranged between $2.01 and $2.86.

Past 12 Months
-24.8%
-35.0%
-42.6%
-48.1%
+12.0%
+15.7%
1W -$0.68
1M -$1.11
3M -$1.53
6M -$1.91
YTD +$0.22
1Y +$0.28

ADAG was +15.7% over the past year, -48.1% over six months, +12.0% year to date, -24.8% in the last week.

12 Months vs Market
ADAG
+15.7%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months ADAG returned +15.7% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 1.33× 3-mo avg
Today 379,602 3-mo avg 286.1K
1W
455.3K
1M
375.9K
3M
286.1K
6M
257.4K
YTD
249.9K
1Y
224.8K

ADAG most recently traded 379,602 shares against a 3-month average daily volume of 286.1K.

More News

Read More
News headline image
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
September 22, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
September 10, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
September 09, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Participate in Three Upcoming Investor Conferences
August 20, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
August 12, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer ↗
May 19, 2026
Via MarketBeat
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
May 12, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
April 14, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
April 02, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 02, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
April 02, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
April 01, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
March 17, 2026
From Adagene Inc.
Via GlobeNewswire
Top movers in Wednesday's session ↗
March 11, 2026
Via Chartmill
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
February 17, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Provides Business Update and 2026 Objectives
January 23, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
December 16, 2025
Via Chartmill
News headline image
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
November 13, 2025
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
November 11, 2025
Via Benzinga
News headline image
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025
From Adagene Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 2.060
When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 10/16/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap